Long‐term mortalityc · children and adults with sepsis
Corticosteroids showed no clear difference in long‐term mortalityc compared with placebo or usual care (low certainty).
1 finding from 1 review
Hospital mortality · children and adults with sepsis
Corticosteroids probably leads to lower hospital mortality compared with placebo or usual care (moderate certainty).
1 finding from 1 review
ICU length of stay (general intensive care patients) · children and adults with sepsis
1 finding from 1 review
Duration of hospital stay MCID: 1 day absolute difference · children and adults with sepsis
1 finding from 1 review
Number of participants with adverse events ‐ superinfection (up to longest · children and adults with sepsis
Corticosteroids showed no clear difference in number of participants with adverse events ‐ superinfection (up to… compared with placebo or usual care (moderate certainty).
1 finding from 1 review
Number of participants with adverse events ‐ muscle weakness (up to longest · children and adults with sepsis
Corticosteroids leads to higher number of participants with adverse events ‐ muscle weakness (up to… compared with placebo or usual care (high certainty).
1 finding from 1 review
Mortality ‐ adults · people with community‐acquired pneumonia
Corticosteroids probably leads to lower mortality ‐ adults compared with control (moderate certainty).
1 finding from 1 review
Mortality ‐ adults ‐ severe CAP · people with community‐acquired pneumonia
Corticosteroids probably leads to lower mortality ‐ adults ‐ severe CAP compared with control (moderate certainty).
1 finding from 1 review
Mortality ‐ adults ‐ non‐severe CAP · people with community‐acquired pneumonia
Corticosteroids showed no clear difference in mortality ‐ adults ‐ non‐severe CAP compared with control (moderate certainty).
1 finding from 1 review
Early clinical failure ‐ adults · people with community‐acquired pneumonia
Corticosteroids probably leads to lower early clinical failure ‐ adults compared with control (moderate certainty).
1 finding from 1 review
Early clinical failure ‐ adults ‐ severe CAP · people with community‐acquired pneumonia
Corticosteroids leads to lower early clinical failure ‐ adults ‐ severe CAP compared with control (high certainty).
1 finding from 1 review
Early clinical failure ‐ adults ‐ non‐severe CAP · people with community‐acquired pneumonia
Corticosteroids leads to lower early clinical failure ‐ adults ‐ non‐severe CAP compared with control (high certainty).
1 finding from 1 review
Early clinical failure ‐ children · people with community‐acquired pneumonia
Corticosteroids leads to lower early clinical failure ‐ children compared with control (high certainty).
1 finding from 1 review
Incomplete recovery at end of study House‐Brackmann scale, Sunnybrook score, Yanagihara score · Bell's palsy
Corticosteroids leads to lower incomplete recovery ≥ 6 months after randomisation House‐Brackmann… compared with placebo or no treatment (high certainty).
1 finding from 1 review
Cosmetically disabling persistent sequelae ≥ 6 months after randomisation Clinical assessment · Bell's palsy
Corticosteroids showed no clear difference in cosmetically disabling persistent sequelae ≥ 6 months after… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Motor synkinesis or crocodile tears Clinical assessment · Bell's palsy
Corticosteroids probably leads to lower motor synkinesis and crocodile tears Clinical assessment compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Adverse effects · Bell's palsy
Corticosteroids showed no clear difference in adverse effects compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Prolongation of time to loss of ambulation ‐ not reported · patients with Duchenne muscular dystrophy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in average muscle score: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review
Nine‐metre walking/running time: prednisone ‐ daily dose regimen (0.75 mg/kg/day) · patients with Duchenne muscular dystrophy
1 finding from 1 review